This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
Part 4. Thalidomide for Multiple Myeloma (continued)
The search strategy was constructed by combining three concepts:
- The intervention thalidomide.
- The disease multiple myeloma.
- Prospective clinical trials.
To identify the intervention concept, we used the MeSH heading thalidomide and text word searching for the following text strings: thalidomid and thalidomide$. The disease concept was implemented using the text word and MeSH® heading searching for multiple myeloma. A published strategy, validated for finding randomized controlled trials (RCTs), was used to identify prospective clinical trials. This strategy is designed to find all prospective clinical trials (maximize sensitivity), rather than to eliminate non-randomized trials (maximize specificity), and so is appropriate for this study's goal of finding phase II and III prospective clinical trials. Finally, the three concepts were combined (Boolean "or"). The strategy was executed in MEDLINE® (1966 through September 2004, updated August, 2005) and limited to articles published in the English language. The exact text of the OVID MEDLINE® versions of the search strategy is provided in Appendix A.
Supplemental searches were conducted in International Pharmaceutical Abstracts, The Cochrane Library (Central Register of Controlled Trials (CENTRAL) and Health Technology Assessment (HTA) database), American Society of Hematology 2004 annual meeting abstracts database, and in the American Society of Clinical Oncology 2004 and 2005 annual meeting abstracts databases. References lists of identified studies and relevant systematic reviews and meta-analyses were hand-checked. Additional articles not indexed in the major bibliographies by August 2005 were identified through ongoing searches and discussions with field experts and monitoring new sources.
Each citation identified from the search strategies was evaluated according to the following selection criteria. Evaluations were performed by the authors.
Inclusion criteria were as follows:
Patients: Patients with multiple myeloma.
- For efficacy questions: Prospective clinical trials; may be phase II uncontrolled, or phase III randomized controlled trials.
- For studies of adverse effects: May be retrospective or prospective case series, cohort studies, or clinical trials provided the number of patients treated (at risk for adverse effects) as well as the number with adverse effects can be ascertained.
- For studies of predictors of response: May be retrospective or prospective case series, cohort studies, case-control studies, or clinical trials provided the response can be ascertained for patients with and without the predictor.
- For efficacy questions: Survival, disease-free survival, tumor response, and quality of life (QOL). Tumor response was defined according to Figure 8.
- For studies of adverse effects:Adverse effects, tolerability, and compliance with treatment.
- For studies of predictors of response: Predictive value of patient or tumor characteristics that are associated with clinically important differences in treatment response that are:
- Related to the mechanism of action of the drug (i.e., molecular target).
- Candidates for diagnostic testing (even if not commercially or clinically available currently [e.g., Polymerase Chain Reaction]).
The following data were abstracted from included studies: study design, population characteristics (including sex, age, and diagnosis), eligibility and exclusion criteria, interventions (dose and duration), outcomes assessed and results for each outcome.
We developed data collection forms in Excel (Microsoft®; Redmond, WA) and summarized the data in evidence tables formatted like those in a 2003 report from the National Institute for Clinical Excellence (NICE) on imatinib for gastrointestinal stromal cell tumors.40
We assessed the quality of included studies by evaluating elements of internal validity (e.g., randomization and allocation concealment; similarity of compared groups at baseline; specification of eligibility criteria; blinding of assessors, care providers, and patients) and external validity (e.g., description of the patient population, similarity to the target population of the report, use of highly selective criteria).
We used as a framework the quality assessment criteria from NICE.40 These are displayed in Appendix B. They provide specific criteria for the range of study designs used in this report including experimental studies, cohort studies, case-control studies, and case series.
Point scores were allocated by assigning one point for each quality category. There were a total of 6 possible categories. Quality ratings of "yes" to a quality criteria were assigned one point; no and unknown were both assigned zero points. The last category, adequate description of subseries, was not applicable to all studies. Hence, the total possible quality points were five or six depending upon the applicability of the subseries category. High quality studies were those with ≥4/6 points. Individual points for each article are summarized in the Appendix B table.
Abstract quality was not scored.
In addition to the data abstraction and quality analysis, a narrative description of study findings was prepared. Further quantitative analyses were considered, but the available data were not adequate to support these.
Since the various studies included in this review variably used the different response criteria or created their own, we have reported all of the paraprotein responses from the various studies using the same format according to the following cut-offs (Figure 9).
Numbers were not provided for all of the categories in all of the studies. When a particular number was not available it was reported as "not stated" (NS).
When comparing response rates with the original studies for VBCMP, VAD, or other chemotherapeutic interventions for multiple myeloma, it is important to consider the definition of response used in the individual studies in order to ensure that like comparisons are made. It can be misleading to just compare the PPR50 percent rows, as some studies report PPR50 percent to mean all responses that were greater than 50 percent (i.e., 50-100 percent) and others indicate just those reflected in that response level (e.g., 50-74 percent with next response level at 75 percent).
Return to Contents
Proceed to Next Section